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What are the novel findings of this work? 
The rate of miscarriage after chorionic villous sampling (CVS) is highly dependent 
on the patient-specific background risk of miscarriage without CVS. Because the 
several factors that lead to CVS are also associated with spontaneous miscarriage, 
in women at low-risk of aneuploidies, CVS is associated with a significant increase 
in the miscarriage rate while, paradoxically, when the risk is high, the risk of 
miscarriage after CVS is reduced, presumably due to prenatal diagnosis and 
termination of major aneuploidies that would have otherwise resulted in spontaneous 
miscarriage. 
What are the clinical implications of this work? 
The true procedure-related risk of miscarriage from CVS can only be derived by 
examining women at low-risk of aneuploidies and in such women their risk of 
miscarriage increases by about three times after CVS. Although this is a substantial 
increase in relative terms, in pregnancies without prior risk factors the risk of 
miscarriage after CVS will still remain low and similar to or slightly higher than that 
of the general population. 




Objective: To estimate the risk of miscarriage associated to chorionic villus sampling 
(CVS). 
Methods: This was a retrospective cohort study performed in eight fetal-medicine 
units in Spain, Belgium and Bulgaria. Two populations were included: first, all 
singleton pregnancies attending to their first-trimester assessment in Murcia, Spain, 
and second, all singleton pregnancies having a CVS following first-trimester 
assessment at any of the participating centers. We used propensity score matching 
analysis to estimate the association between CVS and miscarriage. We compared 
risks of miscarriage of CVS and non-CVS groups after propensity score matching 
(1:1 ratio). This procedure creates two comparable groups balancing the maternal 
and pregnancy characteristics that lead to CVS, in a similar way in which 
randomization operates in a randomized clinical trial.  
Results: The study population consisted of 22,250 participants in the non-CVS group 
and 3,613 in the CVS group. The incidence of miscarriage in the CVS group was 
2.1% (77/3,613), which was significantly higher than the 0.9% (207/22,250) in the 
non-CVS group (p <0.001). The propensity score algorithm matched 2,122 CVS 
cases with 2,122 non-CVS cases including 40 (1.9%) and 55 (2.6%) miscarriages in 
the CVS and non-CVS groups, respectively (OR 0.72 [95% CI 0.48 to 1.10]; p = 
0.146). However, we found a significant interaction between the CVS risk of 
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miscarriage and the risk of aneuploidies, suggesting a different effect of the CVS for 
different baseline characteristics in such a way that, when the risk of aneuploidies is 
low, the risk after CVS increases (OR 2.87 [95% CI 1.13 to 7.30]) but when the risk 
is high, the risk after CVS is paradoxically reduced (OR 0.47 [95% CI 0.28 to 0.76]), 
presumably due to prenatal diagnosis and termination of major aneuploidies that 
would have otherwise resulted in spontaneous miscarriage. 
Conclusions: The risk of miscarriage in women having a CVS is about 1% higher 
than in women without CVS, although this excess risk is not entirely due to the 
invasive procedure but to some extent the demographic and pregnancy 
characteristics of the patient undergoing CVS. After accounting for these risk factors 
and confining the analysis to low-risk pregnancies, CVS seems to increase the risk 
of miscarriage about three times above the patient’s background-risk. Although this 
is a substantial increase in relative terms, in pregnancies without risk factors, the risk 
of miscarriage after CVS will still remain low and similar to or slightly higher than that 
of the general population. For example, if her risk of aneuploidy is 1 in a 1,000 
(0.1%), her risk of miscarriage after CVS will increase to 0.3% (0.2% higher). 
 




Chorionic villous sampling (CVS), which was first described in 19751 and introduced 
into widespread practice in the 1980’s, is a useful invasive test for early prenatal 
diagnosis of chromosomal and genetic abnormalities. The procedure related risk of 
miscarriage was not investigated in studies that randomized women into CVS vs. 
non-invasive testing groups. However, the risk was derived indirectly through first, 
randomized control trials (RCTs) comparing CVS with first or second trimester 
amniocentesis, and second, comparison of rates of miscarriage in groups with 
similar risk factors that had CVS with those that did not have invasive testing. The 
results of trials established that first, the risk of miscarriage following CVS was lower 
than that of early amniocentesis but similar to that of mid-trimester amniocentesis, 
and second, the risk of transabdominal and transcervical CVS was similar.2-7 
Consequently, since the only trial comparing mid-trimester amniocentesis to 
expectant management reported a 1% higher risk of miscarriage in the 
amniocentesis group,8 it was assumed that the risk of miscarriage from CVS was 
also about 1%. 
Another approach for estimating the procedure-related risk of miscarriage from 
CVS is to compare rates of miscarriage in groups that had CVS with those that did 
not have invasive testing. However, such an approach is likely to provide a bias 
against CVS because several of the factors that lead to CVS are also risk factors for 
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miscarriage, i.e. increased maternal age, increased fetal nuchal translucency (NT), 
low serum pregnancy associated plasma protein-A (PAPP-A), and abnormal flow in 
the fetal ductus venosus.9-13 One possible approach to overcome this problem, is to 
carry out logistic regression analysis to identify predictors of miscarriage in women 
who did not have CVS and then apply the model to women who had CVS and 
compare the observed to the expected number of miscarriages in the latter group.13-
15 A second approach is to perform a propensity score (PS) analysis that creates two 
homogeneous groups suitable for comparisons.16 PS analysis has emerged as a 
robust methodology well suited to estimate causal effects from observational data 
while accounting for a greater number of confounder effects than classical 
multivariate analysis could adjust for.17,18 Studies utilizing these approaches 
reported that the procedure-related risk of miscarriage from CVS may be 
considerably lower than 1%.13-16 A recent meta-analysis included 7 studies 
comparing 13,011 women who had a CVS with 232,680 women who did not have 
the procedure and estimated the risk of miscarriage following CVS at 0.20% (95% 
CI, −0.13 to 0.52%).19 However, the results from the different studies were 
heterogeneous and the value of pooled estimates from meta-analyses in such cases 
is questionable.20   
The main objective of this multicenter study was to estimate the CVS-related risk 
of miscarriage after accounting for the effect of maternal and pregnancy 
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characteristics which could have driven the decision around performing or not a 
CVS.  
 




Study design and population 
This is a retrospective cohort study performed at eight fetal-medicine units in Spain 
(Hospital Clínico Universitario Virgen de la Arrixaca in Murcia, Hospital Clínico 
Universitario San Cecilio and Hospital Universtario Virgen de las Nieves in Granada, 
Hospiten de Tenerife in Tenerife and Hospital Universitario de Cruces in Bilbao), 
Belgium (Brugmann University Hospital in Brussels) and Bulgaria (Shterev Hospital 
and OSCAR Clinic in Sofia). In the participating centers women attended for a 
routine ultrasound examination at 11+0-13+6 weeks’ gestation. During this visit patient 
characteristics and medical history were recorded, ultrasound examination was 
carried out to assess viability, diagnose major defects and measure fetal crown-rump 
length (CRL) and fetal NT thickness and assess ductus venosus a-wave as positive 
or negative / reversed. Blood was also collected in the same visit (n = 651 [2.5%]) or 
1-2 weeks previously (n= 25,212 [97.5%]) for measurement of serum free β-human 
chorionic gonadotropin (β-hCG) and PAPP-A. Screening for trisomies 21, 18 and 13 
was carried out using The Fetal Medicine Foundation algorithm, which combines 
maternal age, fetal NT, ductus venosus flow and multiple of the median (MoM) 
values of free β-hCG and PAPP-A.21 The estimated risk for trisomies was then used 
to counsel women and in those choosing invasive testing CVS was performed by the 
same transabdominal technique by or under the supervision of a fetal medicine 
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expert trained at King’s College Hospital, London, UK. Pregnancies were dated 
according to the fetal CRL at the time of screening if they were naturally conceived22 
and according to conception date if they were conceived by in-vitro fertilization. 
We recorded the following patient characteristics: maternal age, weight, height, 
racial origin (White, Black, South Asian, East Asian and mixed), method of 
conception (natural or assisted conception requiring the use of ovulation drugs or in-
vitro fertilization), cigarette smoking during pregnancy (yes or no) and parity (parous 
or nulliparous if no previous pregnancy at ≥ 24 weeks’ gestation), and medical history 
of diabetes mellitus and chronic hypertension (yes or no).  
Two populations were included in this study; first, all singleton pregnancies 
attending to their first-trimester assessment in Murcia (Spain) who did not have CVS, 
and second, all singleton pregnancies having a CVS following first-trimester 
assessment at any of the participating centers. In the control group there were 
21,873 (98.3%) pregnancies with a low-risk from the first-trimester combined test, 
345 (1.6%) with a high-risk and 32 (0.1%) who declined risk assessment. Indication 
for CVS was mainly increased risk for aneuploidies but also increased NT, history of 
genetic disease in the family, previous aneuploidy or even maternal request. The 
patients were examined between July 2007 and June 2018. The eligibility criteria 
were singleton pregnancy with a live fetus at 11+0 to 13+6 weeks without genetic 
anomalies or major fetal defects (such as acrania, holoprosencephaly, megacystis, 
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exomphalos, congenital heart defects) diagnosed before or after birth. We excluded 
pregnancies resulting in termination for any reason, pregnancies without follow up 
and pregnancies having an amniocentesis later on in pregnancy. 
The primary outcome measure was miscarriage, defined as pregnancy loss 
occurring before 24 weeks’ gestation regardless of the interval between CVS and 
fetal demise. Results of the investigations and pregnancy outcome were recorded in 
computer databases. Approval for the study and waiver of consent was obtained 
from the relevant research ethics committee in each center in which the study was 
conducted.  
Statistical analyses  
Descriptive data were expressed as median and interquartile range (IQR) and in 
proportions (absolute and relative frequencies). Comparisons between treatment 
groups were performed by Mann-Whitney U-test or two-tailed χ2-test as appropriate. 
Analyses were run on a complete case basis, and the number of pregnancies 
included in each analysis were reported wherever necessary. Level of significance 
was set at 0.05. 
Because we noted important differences in baseline clinical characteristics 
between the CVS and the non-CVS groups, we performed a propensity score 
matching analysis to assess the effect of CVS in the risk of miscarriage adjusting for 
the confounding bias caused by this imbalance. Compared with classic multivariate 
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adjustments, the PS permits finer adjustments for wider sets of covariates. The PS 
was defined as the conditional probability of having a CVS given the measured 
covariates in order to balance covariates in the two groups. To obtain the PS, we 
fitted a logistic regression model with CVS as dependent variable and then we 
modelled the conditional probability of having a CVS as a function of baseline and 
those clinical characteristics associated with having a CVS. We use the PS to match, 
without replacement, each complete CVS case with the non-CVS case with the 
closest PS in a 1:1 ratio, to optimise the precision of the estimate of association and 
limit bias. We also accepted cases only if the difference in PS between matched 
cases was small (calliper of 0.1), resulting in excellent balance between the CVS 
and the non-CVS cases as matched samples.23 We computed standardised 
differences for all variables included in the PS before and after matching to assess 
the effect of matching on the imbalance. We deemed a 10% standardized difference 
as the limit for a correct balance. After matching, we compared miscarriage rate 
between the CVS cases and those without CVS as matched groups. Finally, we 
calculated an odds ratio (OR) to quantify the association between CVS and 
miscarriage using a univariate logistic regression fitted by generalised estimating 
equations to account for matched data. 
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The statistical software package R was used for data analyses. 24 The R package 
MatchIt25 was used for matching with PS. Analysis of matched cases was performed 
using the R package Geepack.26 
 





The study population consisted of 22,250 participants in the non-CVS group and 
3,613 in the CVS group (figure 1). Maternal and pregnancy characteristics are shown 
in Table 1. In the CVS group, compared to the non-CVS group, median maternal 
age, gestational age, fetal NT and serum free β-hCG MoM were significantly higher 
and maternal weight and PAPP-A MoM were lower, and the incidence of parous 
women, Black or South Asian racial origin, chronic hypertension and conception by 
assisted reproductive techniques and abnormal flow in the fetal ductus venosus was 
higher. The only parameter not significantly different was the frequency of pre-
existing diabetes mellitus.  
The incidence of miscarriage in the CVS group was 2.1% (77/3,613), which was 
significantly higher than the 0.9% (207/22,250) in the non-CVS group (p <0.001).  
Procedure-related risk of miscarriage 
We calculated PS for each case in the study population based on their probability of 
having a CVS. Multivariable regression analysis demonstrated that significant 
predictors associated to having a CVS were increasing maternal age, decreasing 
maternal weight, assisted conception, chronic hypertension, increasing gestational 
age, high fetal NT, abnormal flow in the ductus venosus, high free β-hCG and low 
PAPP-A (Table S1).  
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The PS algorithm matched 2,122 of our CVS cases with 2,122 non-CVS 
pregnancies, largely reducing the initial imbalance between women with and without 
CVS, with between-group standardized differences for all instances lower than the 
recommended 10% limit (figure 2, tables 1 and 2). The number of miscarriages was 
40 (1.9%) in the CVS group and 55 (2.6%) in the matched non-CVS group. PS 
analysis did not find any significant association between CVS and miscarriage (OR 
0.72 [95% CI 0.48 to 1.10]; p=0.146). We hypothesized that the most likely 
explanation for this paradoxical effect of CVS “decreasing” the risk of miscarriage 
was that many of the cases that would have resulted in spontaneous miscarriage 
had the pregnancy continued, were converted into elective pregnancy terminations 
following an abnormal genetic diagnosis. If this was true, this “protective” effect 
should be higher in cases at high-risk of having a genetic anomaly and lower in cases 
at low-risk. 
Therefore, we aimed to investigate whether the effect of having a CVS was the 
same in women at higher risk of aneuploidies as compared to those at lower risk. 
Thus, we investigated a possible interaction between the risk of aneuploidy and 
CVS. Since the risk factors associated to having a CVS are the same factors that 
increase the risk of aneuploidies, we divided our 4,244 matched cases in two equal 
groups by the median of the PS. The median PS was 0.402 (IQR 0.331-0.490) in the 
high-risk subgroup (n=2,122) and 0.131 (IQR 0.057, 0.197) in the low-risk subgroup 
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(n=2,122). In the high-risk subgroup there were 1,062 cases having a CVS, including 
23 (2.2%) miscarriages and 1,060 non-CVS cases, including 49 (4.6%) miscarriages 
(OR 0.47 [95% CI 0.28 to 0.76]); in contrast, in the low-risk subgroup we found 17 
(1.6%) miscarriages in the CVS (n = 1,060) group compared to 6 (0.6%) 
miscarriages in the non-CVS (n= 1,062) group (OR 2.87 [95% CI 1.13 to 7.30]. Both 
effects were statistically different (p value of the interaction = 0.0003) (figure 3). 
These results suggest that there is something which makes the CVS behave 
differently when the risk of aneuploidies is high compared to when it is low. Thus, 
using the PS as a proxy of the risk of aneuploidies, for a patient with a 10% 
probability of aneuploidy based on her pregnancy characteristics, the risk of 
miscarriage after the procedure is still very high but halved to about 5%, suggesting 
that in such case CVS is highly “protective” of miscarriage. However, for a patient 
with a low probability of aneuploidy, her risk of miscarriage will increase. For 
example, if her risk of aneuploidy is 1 in a 1,000 (0.1%), her risk of miscarriage after 
CVS will increase to 0.3% (0.2% higher) or, in other words, we would need to perform 
500 CVSs to cause a miscarriage. Further analysis on this interaction is provided in 
Appendix 1. 
 





In this study we found that: first, following a first trimester scan demonstrating a 
structurally normal fetus, the risk of subsequent miscarriage for the general 
population is about 1%; second, in women having CVS the risk of miscarriage is 
about 1% higher than in women without CVS although this excess risk is not entirely 
due to the invasive procedure but to some extent the demographic and pregnancy 
characteristics of the patient undergoing CVS; and third, the actual procedure-
related risk of the CVS may only become apparent in patients at low risk of 
aneuploidies and, in these cases, the risk of miscarriage after CVS increases by 
about three times.  
We have demonstrated that, although in women at high-risk of aneuploidies CVS 
appears to be “protective” against miscarriage, the most likely explanation for this 
observation is that CVS leads to the diagnosis of major aneuploidies followed by 
elective pregnancy termination in cases that would have otherwise resulted in 
spontaneous miscarriage. In the CVS group we excluded 22.2% (1,135/5,112) of 
cases because of termination of pregnancy or fetal defects, compared to only 4.2% 
(1,070/25,519) in the non-CVS group (figure 1). Had these cases been included and 
the pregnancy had continued, many would have resulted in miscarriage and then the 
rate of miscarriage in the CVS group would have been considerably higher than in 
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the non-CVS group. To try to avoid this selection bias, we studied separately the 
effect of the CVS in cases with a low probability of having a CVS and in those with 
a higher probability. Contrary to what happens in high-risk cases, in women at low 
risk of aneuploidies, the procedure significantly increases this risk by about three 
times.  
Comparison with findings of previous studies 
Our results offer an explanation for the contradictory findings of previous studies that 
showed that CVS did not significantly modify the risk of miscarriage, and a meta-
analysis that reported a non-significant “protective” effect of CVS against 
miscarriage17.  
First, one large study examined 31,460 pregnancies undergoing first-trimester 
combined screening for aneuploidies without CVS and identified risk factors for 
miscarriage.13 They then applied this model in 2,396 pregnancies with CVS and 
found that the estimated number of miscarriages was 45 (95% CI 32 to 58) which 
was similar to the observed number of 44.13 Two subsequent studies following a 
similar methodology did not find significant differences between groups.14,15  
Second, a large national registry-based study assessing 147,987 singleton 
pregnancies that had first-trimester combined screening for aneuploidies, including 
5,072 that had CVS, reported that the average effect of CVS on risk of miscarriage 
was -0.21% (95% CI, -0.58 to 0.15).16 In this study the CVS-related risk of 
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miscarriage was assessed by a dynamic PS stratification approach.16 The 
advantage of this approach is that it allows use of the whole sample but the major 
disadvantage is that the higher the number of cases per stratum the greater is the 
difference in baseline characteristics of the patients even within the same stratum. 
In our matching approach we used a 1:1 ratio and a small difference in PS between 
matched cases (calliper of 0.1) to ensure that the CVS and non-CVS groups had a 
very similar risk-profile.  
Third, a recent RCT randomized women at high-risk of aneuploidies into cell-
free DNA testing (n = 1,015) or invasive testing, both amniocentesis or CVS (n = 
982), and found not significant differences in the risk of miscarriage between the two 
groups (0.8% vs. 0.8%, for a risk difference of −0.03% (1-sided 95%CI, −0.68% to 
∝; P = 0.47).25 
Clinical implications 
In those cases where there is a clear indication to perform prenatal genetic testing, 
we can reassure women that their risk of miscarriage mainly depends on the results 
from genetic diagnosis and the conditions that lead to it more than the procedure 
itself. However, in the absence of any major fetal defect or other additional risk 
factors for chromosomal abnormalities, we should report an individualized 
procedure-related risk based on women clinical characteristics. 
Strengths and limitations  
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The main limitations of the study derive from its observational and retrospective 
nature with the immediate consequence of the heterogeneity between comparison 
groups (figure 2). Although we tried to mitigate these differences, we were able to 
balance only those maternal and pregnancy characteristics that had been recorded, 
therefore, we cannot disregard the possibility of some residual confounding. 
Additionally, we could not assess the influence of technical factors or experience of 
operators since they are not routinely recorded in any of the participating centers; 
however, its influence in the risk of miscarriage is well studied26,27. Fetal karyotype 
was not available in most cases miscarrying spontaneously and therefore our 
assumption on increased rate of aneuploidies among them remains hypothetical. 
We chose to exclude aneuploidies and fetal defects from the analysis because these 
would overestimate the risk of miscarriage in the CVS group, since they are the 
cases most likely to miscarry. However, this exclusion inevitably leads to the 
opposite effect as shown in our results: underestimation of the procedure-related risk 
due to lack of knowledge about karyotype in most of the miscarriages in the non-
CVS group while the CVS sample is “clean” of aneuploidies.  
The main strength of our study relates to the large sample of both, CVS and non-
CVS cases, which were selected after matching women of both groups but with 
identical propensity of CVS. Since the matching was indirectly based on known risk-
factors for aneuploidies, we were able to perform subgroup analysis to demonstrate 
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the interaction between the risk of aneuploidies and CVS by comparing patients with 
a very similar risk-profile.  
All invasive procedures were performed by the same technique and by fetal 
medicine experts or their trainees at the end of such training. This represents both 
an advantage, because this reduces the variability between operators, and a 
disadvantage, since the results might not be valid for different approaches and level 
of expertise.  
Conclusions 
The risk of miscarriage in women having a CVS is about 1% higher than in women 
without CVS, although this excess risk is not entirely due to the invasive procedure 
but to some extent to the demographic and pregnancy characteristics of the patient 
undergoing CVS. After adjusting for these risk factors and confining the analysis to 
low-risk pregnancies, CVS seems to increase the risk of miscarriage about three 
times above the patient’s background-risk. Although this is a substantial increase in 
relative terms, in pregnancies without risk factors, the risk of miscarriage after CVS 
will remain low and similar to or slightly higher than that of the general population. 
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Figure 1. Flow diagram of patients included in the study. CVS, chorionic villus 
sampling. 
 
Figure 2. Propensity score matching of cases with chorionic villus sampling with 
cases without chorionic villus sampling. The grey band denotes 10% standardised 
difference between covariates.  
 
Figure 3. Odds ratio for miscarriage after chorionic villus sampling in women with 
high and low risk of having a CVS. CVS, chorionic villus sampling. 
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Table 1. Maternal and pregnancy characteristics of the study population.  
Variable 
Non-chorionic 
villus sampling*  
(n = 22,250) 
Chorionic villus 
sampling 




Maternal age, y 32.5 (28.4, 35.8) 35.2 (31.4, 38.3) <0.0001 49.0 
Maternal weight, kg 64.0 (57.3, 73.0) 63.5 (57.0, 72.0) 0.0014 -5.4 
Maternal height, cm 163 (160, 168) 163 (159, 167) 0.0281 -3.4 
Racial origin    6.0 
White 21937 (98.6) 3526 (97.6) <0.0001  
Black 221 (1.0) 52 (1.4) 0.0190  
South Asian 21 (0.1) 13 (0.4) 0.0001  
East Asian 71 (0.3) 22 (0.6) 0.0108  
Method of conception   0.0048 4.9 
Natural 21258 (95.5) 3413 (94.5)   
Assisted 992 (4.5) 200 (5.5)   
Parity    18.0 
Nulliparous 10246 (46.0) 1345 (37.2) <0.0001  
Parous 12004 (54.0) 2268 (62.8) <0.0001  
Cigarette smoking 3137 (14.1) 467 (12.9) 0.0625 3.4 
Medical history     
Diabetes mellitus 223 (1.0) 40 (1.1) 0.4240 1.7 
Not known 1846 (8.3) 469 (13.0) <0.0001  
Chronic hypertension 157 (0.7) 46 (1.3) <0.0001 7.4 
Not known 66 (0.3) 510 (14.1) <0.0001  
Gestational age, wk 12.6 (12.2, 13.1) 13.0 (12.5, 13.5) <0.0001 50.4 
Delta nuchal translucency, mm 0.16 (-0.06, 0.40) 0.32 (‘-0.01, 0.85) <0.0001 43.4 
Ductus venosus      
Abnormal flow 1059 (4.8) 384 (10.6) <0.0001 26.6 
Not known 907 (4.1) 511 (14.1) <0.0001  
Free β-hCG, MoM 1.05 (0.69, 1.63) 1.29 (0.77, 2.12) <0.0001 28.9 
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Data are given as median (interquartile range) or n (%). *The subset of women included in the 
propensity score regression analysis was taken from this group. hCG = human chorionic 
gonadotropin; PAPP-A = pregnancy associated plasma protein-A; Comparisons between outcome 
groups were by χ2-test for categoric variables and Mann-Whitney U test for continuous variables.  
PAPP-A, MoM 0.94 (0.67, 1.34) 0.52 (0.32, 0.86) <0.0001 -69.1 
Miscarriage, n (%) 207 (0.9) 77 (2.1) <0.0001  
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Table 2. Maternal and pregnancy characteristics of the chorionic villus sampling and non-
chorionic villus sampling cases matched by propensity score. 
Variable 
Non-chorionic 
villus sampling  
(n = 2,122) 
Chorionic villus 
sampling 




Maternal age, y 34.8 (31.5,37.7) 34.7 (31.1,37.9) 0.5789 2.1 
Maternal weight, kg 63.0 (57.0,71.5) 63.0 (56.6,71.2) 0.9949  -0.2 
Maternal height, cm 163 (159,167) 163 (159,167) 0.9582  -0.8 
Racial origin, n (%)   0.8592 1.1 
White 2107 (99.3) 2105 (99.2)   
Non-White 15 (0.7) 17 (0.8)   
Method of conception, n (%)   0.3681 3.0 
Natural 2019 (95.1) 2005 (94.5)   
Assisted 103 (4.9) 117 (5.5)   
Parity, n (%)   1.000 0.1 
Nulliparous 853 (40.2) 854 (40.2)   
Parous 1269 (59.8) 1268 (59.8)   
Cigarette smokers, n (%) 288 (13.6) 272 (12.8) 0.4963 -2.2 
Medical history, n (%)     
Diabetes mellitus (n= 2367; 2450) 20 (0.9) 23 (1.1) 0.8669 1.0 
Chronic hypertension 27 (1.3) 26 (1.2) 1.000 -0.4 
Gestational age, weeks 13.0 (12.5,13.4) 12.9 (12.4,13.4) 0.0414  -7.3 
Delta nuchal translucency, mm 0.33 (0.08,0.65) 0.26 (-0.02,0.65) <0.0001  0.3 
Abnormal flow in ductus venosus  251 (11.8) 232 (10.9) 0.3843 -2.8 
Free β-hCG, MoM 1.19 (0.74,1.91) 1.22 (0.75,1.96) 0.5273 6.3 
PAPP-A, MoM 0.66 (0.48,0.90) 0.52 (0.32,0.87) <0.0001  -9,9 
Miscarriage, n (%) 55 (2.6) 40 (1.9) 0.1463  
Data are given as median (interquartile range) or n (%). Comparisons between outcome groups were 
by chi, square test for categoric variables and Mann, Whitney U test for continuous variables.  
The covariates used to identify matched women without chorionic villus sampling were maternal age, 
weight height and racial origin, method of conception, parity, smoking status, chronic hypertension, 
gestational age, nuchal translucency, free β-hCG and PAPP-A. 
hCG = human chorionic gonadotropin; PAPP-A = pregnancy associated plasma protein-A.   
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Cases screened n = 25,519 
Included for analysis 
n = 22,250 
Amniocentesis / CVS 
n = 1,062 
Loss to follow up 
n = 1,137 
Termination / Major defects 
n = 1,070 
Cases screened n = 5,112 
Included for analysis 
n = 3,613 
Amniocentesis  
n = 103 
Loss to follow up 
n = 261 
Termination / Major defects 
n = 1,135 
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